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MaST-segment elevation myocardial infarction (STEMI) remains a signiﬁcant global public health concern. Practice guidelines
in both the United States and Europe have been major contributors to providing evidence-based care. Rapid advances in
contemporary therapies mandate regular and timely updates to guideline recommendations. In the fall of 2012, the Eu-
ropean Society of Cardiology published their latest guidelines for the management of STEMI. In 2013 (w3 months later),
the American College of Cardiology Foundation and the American Heart Association jointly published their most recent
STEMI guideline statements. In this review, we compare the transatlantic guidelines, highlighting differences in their
recommendations and the interpretation of evidence addressing STEMI care. (J Am Coll Cardiol 2016;67:216–29)
© 2016 by the American College of Cardiology Foundation.C ardiovascular medicine has witnessed re-markable advances in the care of patientswith acute coronary syndromes (ACS). This
is no more dramatically evident than in the manage-
ment of myocardial infarction (MI) and is well
captured by the evolution of care guidelines ﬁrst arti-
culated for MI by the American College of Cardiology
Foundation (ACCF)/American Heart Association
(AHA) in 1990 (1) and by the European Society of Car-
diology (ESC) in 1996 (2). Subsequently, speciﬁc
guidelines aimed at ST-segment elevation myocardial
infarction (STEMI) emerged on both sides of the
Atlantic, along with regular updates that culminated
in recent major revisions occurring within 3 months
of each other (3,4). Our purpose here is to highlight
particular areas where differences exist in either
emphasis or interpretation and how they inﬂuence
the recommendations that follow. In undertaking
this review, we are conscious that the target audience
for the ACCF/AHA guidelines is more homogeneous
than the more eclectic audience for the ESC, whichm the Canadian VIGOUR Centre, Mazankowski Alberta Heart Institute,
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litical jurisdictions. In context, we also appreciate
that this is a rapidly evolving ﬁeld, where these rec-
ommendations may change on the basis of new evi-
dence forthcoming since their publication (5,6).
Some initial general observations are in order. The
2012 ESC cites 346 references in their 2012 document,
whereas the ACCF/AHA cite 656 references (almost
double) in their full-text 2013 version. Although both
documents use the traditional 3 classes of recom-
mendations and levels of evidence (LOEs), the ACCF/
AHA have, for the ﬁrst time, subdivided the Class III
category into those assigned as having no beneﬁt
versus those with the potential for harm. Unlike the
ESC, the ACCF/AHA guidelines also speciﬁcally inte-
grate the classes of recommendation and levels of
evidence in an attempt to gauge both the magnitude
of expected beneﬁt and the certainty with which it
can be anticipated.
As seen in Figure 1, the Europeans provide a
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AB BR E V I A T I O N S
AND ACRONYM S
ACCF = American College of
Cardiology Foundation
ACS = acute coronary
syndromes
AHA = American Heart
Association
DAPT = dual antiplatelet
therapy
ESC = European Society of
Cardiology
FMC = ﬁrst medical contact
LOE = level of evidence
MI = myocardial infarction
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
= unfractionated heparin
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217(ESC 164 vs. ACCF/AHA 122). Although both sets of
guidelines share common themes, as evident in the
central panel of Figure 1, there are unique character-
istics for each, as noted in the margins (3,4). When
these recommendations are categorized according to
their respective LOE (Figure 2), the majority from both
sets of guidelines are Class I. However, the minority of
these Class I recommendations are supported by LOE A
(ACCF/AHA 19% vs. ESC 25%). Although this repre-
sents amodest improvement over the 10.7% fraction of
LOE: A supporting the Class I STEMI recommendations
in the 2004 ACCF/AHA STEMI guidelines (7), it also
highlights that further evidence is required in areas of
clinical need (8).
ELECTROCARDIOGRAM DIAGNOSIS
Both guideline committees endorse the ESC/ACCF/
AHA Universal Deﬁnition of Myocardial Infarction for
the diagnosis of STEMI (9,10). However, given the
timing of publication (i.e., after the ESC guidelines),
the ACCF/AHA understandably uses a more contem-
porary deﬁnition (i.e., the Third Universal Deﬁnition
of Myocardial Infarction [10]). Hence, the ACCF/AHA
guidelines include new ST-segment elevation at the J-
point in at least 2 contiguous leads $2 mm (0.2 mV) in
men, $1.5 mm (0.15 mV) in women in leads V2 to V3,
and/or of $1 mm (0.1 mV) in other contiguous chest
leads or the limb leads. The ESC deﬁnes the STEMI
electrocardiogram (ECG) as J-point elevation in 2
contiguous leads with $0.25 mV (0.25 mm) in men
below the age of 40 years, $0.2 mV (0.3 mm) in men
over the age of 40 years, or $0.15 mV (0.15 mm) in
women in leads V2 to V3, and/or $0.1 mV (0.1 mm) in
other leads. The Europeans also strongly advocate the
use of right precordial leads (V3R and V4R) for inferior
MI to identify right ventricular involvement and
posterior chest leads (V7 to V9 $0.05 mV) in patients
with suspected posterior (inferobasal) MI (Class IIa,
LOE: C).
Interestingly, due to its infrequent occurrence, the
ACCF/AHA guidelines have eliminated new left
bundle branch block (LBBB) from the diagnosis of
STEMI and opine that LBBB “should not be consid-
ered diagnostic of acute MI in isolation” (4). However,
the ESC still considers atypical electrocardiogram
presentations in STEMI, such as LBBB and ventricular
paced rhythm, to be worthy potential prospects.
EMERGENCY SUPPORTIVE CARE
Table 1 outlines the recommendations for acute
supportive care in patients with STEMI. Although
both guidelines advocate compassionate therapies,
the ESC provides ofﬁcial recommendations (Class,LOE), whereas the ACCF/AHA guidelines
offer advisory statements about these thera-
pies without recommendations.
MORPHINE. The ACCF/AHA guidelines sug-
gest morphine as the choice of analgesic
agent (opioid) for STEMI to help alleviate
anxiety, reduce the work of breathing
(particularly in patients with acute pulmo-
nary edema), and help reduce ventricular
loading conditions. The ESC is less speciﬁc on
the choice of analgesic agent, but recom-
mends the general use of intravenous opioids
to help relieve pain (Class I, LOE: C).
OXYGEN. Inhaled oxygen is promoted by
both organizations; however, the ACCF/AHA
guidelines are cautious and suggest sup-
plemental oxygen only for arterial satura-
tions <90% due to the 3-fold increased risk
of death suggested by a Cochrane review of
the data (11) and an observed increase in coronary
vascular resistance with oxygen in acute MI (12).
The ESC strongly recommends that supplemental
oxygen be administered for hypoxia with satura-
tions <95%, breathlessness, or acute heart failure
(Class I, LOC: C).
ASPIRIN LOAD. Immediate therapy with aspirin has
become standard, given the commensurate beneﬁts
observed in the ISIS-2 (Second International Study of
Infarct Survival) study (13). In keeping with the oral
administration in this trial, the ACCF/AHA guidelines
endorse oral administration of aspirin (162- to 325-mg
load) in acute MI (Class I, LOE: B). However, the ESC
recommends either oral (150 to 300 mg) or intrave-
nous formulation (80 to 150 mg) (Class I, LOE: B).
Note that intravenous aspirin is only available in
Europe, and hence is not included in the ACCF/AHA
guidelines.
CHOICE OF REPERFUSION STRATEGY
Because rapid recanalization of the infarct-related
artery is paramount in STEMI, it understandably
takes center stage in both task force recommen-
dations. However, this topic also accentuates key
transatlantic differences relating to both the
modes and timing of reperfusion (Table 2, Central
Illustration). The ACCF/AHA guidelines focus on pri-
mary percutaneous coronary intervention (PCI) as the
leading and preferred mode of reperfusion for pa-
tients with STEMI. For patients presenting at a PCI-
capable hospital, the recommended ﬁrst medical
contact (FMC)-to-device time is within 90 min. For
patients presenting to a non–PCI-capable hospital,
UFH
FIGURE 1 Comparison of STEMI Guidelines
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Guideline Recommendations
122 ACCF/AHA
Guideline Recommendations
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ESC: 5 recommendations
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Acute Symptomatic Relief
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An overall comparison of the 2012 ESC and 2013 ACCF/AHA guidelines. Common themes (blue arrows) and separate recommendations
(orange arrows) are shown. ACCF ¼ American College of Cardiology Foundation; AHA ¼ American Heart Association; CABG ¼ coronary artery
bypass graft; CCU ¼ coronary care unit; ESC ¼ European Society of Cardiology; STEMI ¼ ST-segment elevation myocardial infarction.
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218immediate transfer to a PCI facility for primary PCI is
recommended, with an FMC-to-device time within
120 min. Fibrinolysis is endorsed only if unavoidable
delays occur in excess of 120 min (i.e., PCI-related
delay) (Class I, LOE: B). Of considerable interest is
the differing approach to pre-hospital ﬁbrinolytic
therapy. The ACCF/AHA guidelines suggest that this
strategy might be useful in rural areas, but notes that
such areas have “neither the resources to train para-
medics nor the funding for necessary equipment” (4).
Remarkably, no recommendation is provided, but
rather, a suggestion is made “for further research into
the implementation of pre-hospital strategies to
reduce total ischemic time” (4).
In contrast, the ESC strongly sanctions pre-hospital
logistics of care with a particular focus and Class I,
LOE: B recommendation for the use of pre-hospital
care as a mode for reducing “system delay” (i.e.,
FMC to reperfusion) (Central Illustration). If primary
PCI is considered, patients arriving at a PCI-capablehospital should achieve an FMC-to-device time
within 90 min, but preferably within 60 min of
presentation. The ESC further suggests a more
stringent #60 min FMC-to-device time for high-risk
cases, particularly emphasizing those with large
anterior infarcts, as well as early presenters (within
2 h) who are expected to derive greater myocardial
salvage and incremental beneﬁt from early reperfu-
sion. If presenting at a non–PCI-capable hospital, the
ESC recommends an FMC-to-device time within 120
min, but preferably within 90 min. For high-risk
cases, FMC-to-device time should be preferably
within 60 min, but if these times cannot be achieved
(i.e., within 90 min), then the ESC recommends
ﬁbrinolysis (Class IIa, LOE: B).
PRIMARY PCI. Primary PCI at a high-volume facility,
performedbyanexperienced teamwith 24h/7 days/week
access, is the preferred reperfusion strategy in
patients presenting with STEMI within 12 h of
symptom presentation.
FIGURE 2 Guideline Recommendations According to LOE
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A breakdown of recommendations from the 2012 ESC (n ¼ 164) and the 2013 ACCF/AHA guidelines (n ¼ 122), according to their respective
levels of evidence (LOEs). Abbreviations as in Figure 1.
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219Anc i l la ry pharmacolog ica l therapy . Table 3 pro-
vides a summary of acute pharmacotherapy for pri-
mary PCI in STEMI. The ACCF/AHA supports the use
of all P2Y12 receptor inhibitors with similar levels of
recommendation (clopidogrel, prasugrel, and tica-
grelor all receive Class I, LOE: B). The ESC prefers
prasugrel or ticagrelor to clopidogrel, unless they are
not available or contraindicated (Class I, LOE: C).
Intravenous glycoprotein (GP) IIb/IIIa antagonists
have a Class IIa ACCF/AHA recommendation (LOE: B
[except abciximab, LOE: A]). Intracoronary abciximab
is a consideration for use in the catheterization lab-
oratory (Class IIb, LOE: B). Using the same evidence,
the ESC provides a weaker Class IIb recommen-
dation for intravenous GP IIb/IIIa antagonists as an
adjunct therapy in STEMI (LOE: B [except abciximab,
LOE: A]). No ofﬁcial ESC recommendation is provided
for intracoronary use.TABLE 1 Emergency Care
ACCF/AHA
Recommendation Class, LOE
Analgesia Morphine N/A
Oxygen Saturations <90% N/A
Anxiolytics N/A N/A
Aspirin load Oral (162–325 mg load) Class I, LOE: B
ACCF¼ American College of Cardiology; AHA¼ American Heart Association; ESC¼ EuropeaFor primary PCI, the ACCF/AHA guidelines
recommend unfractionated heparin (UFH) with a 50
to 70 U/kg bolus if a GP IIb/IIIa antagonist is admin-
istered (Class I, LOE: C) or a UFH 70 to 100 U/kg bolus
without a GP IIb/IIIa antagonist (Class I, LOE: C).
Bivalirudin has a stronger recommendation with or
without prior treatment with UFH (Class I, LOE: B)
(14,15). Additionally, the ACCF/AHA guidelines
recommend bivalirudin over UFH and a GP IIb/IIIa
antagonist (Class IIa, LOE: B). The ESC recommends a
lower bolus dose of UFH (50 to 60U/kg) with a GP IIb/IIIa
antagonist (Class I, LOE: C) (70 to 100 U/kg bolus
without a GP IIb/IIIa antagonist, Class I, LOE: C).
Bivalirudin is also preferred over UFH and a GP
IIb/IIIa antagonist (Class I, LOE: B). The ESC recom-
mends enoxaparin with or without a GP IIb/IIIa
antagonist, which is preferred over UFH (Class IIb,
LOE: B). This recommendation was largely supportedESC
Recommendation Class, LOE
IV opioids Class I, LOE: C
Saturations <95% Class I, LOE: C
Tranquilizers Class IIa, LOE: C
Oral (150–300 mg) or IV (80–150 mg) Class I, LOE: B
n Society of Cardiology; IV¼ intravenous; LOE¼ level of evidence; N/A¼ not applicable.
TABLE 2 Comparison of Reperfusion Strategies: Times, Location, and Risk
ACCF/AHA ESC
Primary PCI
PCI-capable hospital FMC-device #90 min FMC-device time #90 min,
but preferably #60 min
Large territory infarct N/A FMC-device #60 min
Early presenter (#2 h) N/A FMC-device #60 min
Non–PCI-capable hospital FMC-device #120 min FMC-device #120 min,
but preferably #90 min
Large territory infarct N/A FMC-device #60 min
Early presenter (#2 h) N/A FMC-device #60 min
Fibrinolysis
In-hospital FMC-needle #30 min FMC-needle #30 min
Pre-hospital N/A FMC-needle #30 min
FMC ¼ ﬁrst medical contact; PCI ¼ percutaneous coronary intervention; other abbreviations as in Table 1.
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220by the ATOLL (Acute Myocardial Infarction Treated
with Primary Angioplasty and Intravenous Enox-
aparin or Unfractionated Heparin to Lower Ischemic
and Bleeding Events at Short- and Long-term
Follow-up) trial, demonstrating clinical beneﬁt
(secondary outcomes) without the increased risk of
bleeding (16). Enoxaparin is not included in the
ACCF/AHA guidelines for treatment of STEMI with
primary PCI.
Late presentation. In patients presenting with >12 h
of symptoms, there are differences in the guideline
recommendations. In patients with 12 to 24 h of
symptoms and evidence of ongoing ischemia, the
ACCF/AHA guidelines indicate that PCI should be
performed with a weaker recommendation (Class IIa,
LOE: B) than the ESC, which more strongly recom-
mends PCI, but with less evidence (Class I, LOE: C).
Both guidelines cite Polish observational registry data
supporting late reperfusion in STEMI (17). However,
for this indication (i.e., ongoing ischemia), the ACCF/
AHA guidelines cite the BRAVE (Beyond 12 Hours
Reperfusion Alternative Evaluation)-2 trial, which is
the only randomized study (n ¼ 347) to address the
utility of PCI versus conservative management in
stable patients presenting subacutely within 12 to
48 h of symptom onset. In this context, the study
found improvements in infarct size with PCI; yet,
there was no improvement in clinical outcome at
30 days (18). The ESC guidelines do refer to the
BRAVE-2 trial in the context of primary PCI in
stable patients (i.e., no evidence of ischemia) pre-
senting 12 to 24 h after symptom onset with a
lower recommendation (Class IIb, LOE: B) (18,19).
In very late presenters (>24 h) who are clinically
stable, the ACCF/AHA guidelines advise against
performing PCI (Class III, LOE: B). The ESC pro-
vides a similar recommendation, but with a higherlevel of evidence (Class III, LOE: A). Both guide-
lines reference OAT (Occluded Artery Trial), which
demonstrated no beneﬁt from PCI to an occluded
infarct-related artery in the nonacute setting of
MI (20).
Access s i te . The ACCF/AHA do not provide guide-
line recommendations for a preferred vascular access
site for cardiac catheterization. In the text, they
indicate radial access should be used when feasible.
The ESC provides ofﬁcial recommendations support-
ing the radial approach, particularly if performed by
an experienced radial operator (Class IIa, LOE: B).
Interestingly, whereas both guidelines reference the
RIVAL (RadIal Vs femorAL access for coronary inter-
vention) trial (21), the ACCF/AHA guidelines report
that the “rates of major bleeding were not lower with
the radial versus femoral access in patients with
STEMI” (4), whereas the ESC found “the radial
approach reduced the incidence of acute bleeding
events especially in ACS” (3).
Stent type . Stent selection has been controversial
since the 2006 BASKET-LATE (BAsel Stent Kosten
Effektivitäts Trial—LAte Thrombotic Events) obser-
vations (22). The ACCF/AHA guidelines advocate use
of a bare-metal stent (BMS) if a high bleeding risk
exists or if there are likely to be issues with dual
antiplatelet therapy (DAPT) compliance (Class I,
LOE: C), given the brief prescribed duration of DAPT
(1 month for BMS, according to ACCF/AHA recom-
mendations). Otherwise, DAPT is recommended for
1 year, given the beneﬁts accrued in ACS (Class I,
LOE: B). However, if a drug-eluting stent (DES) is
placed, clinicians are encouraged to consider DAPT
beyond 1 year (Class IIb, LOE: C). No comments are
made regarding shortening the duration of DAPT
with DES. The ESC prefers DES if no bleeding risk or
compliance issues apply (Class IIa, LOE: A). Sugges-
tions for 12 months of DAPT are similar for ACS
(Class I, LOE: C); however, the ESC provides a strict
minimum of 1 month for BMS (Class I, LOE: C) and
6 months for DES (Class IIb, LOE: B).
Culprit-only versus complete revascularization. Approx-
imately 40% to 50% of patients undergoing primary
PCI have multivessel disease, with at least 1 addi-
tional noninfarct-related artery lesion considered to
be hemodynamically severe. The ACCF/AHA guide-
lines indicate that PCI should not be performed in a
noninfarct artery at the time of primary PCI in he-
modynamically stable patients (Class III, LOE: B). The
ESC recommends limiting primary PCI to the culprit
vessel, with the exception of cardiogenic shock and
persistent ischemia after primary PCI (Class IIa,
LOE: B). Interestingly, both sets of guidelines cite
similar references (23–25).
CENTRAL ILLUSTRATION Transatlantic Comparison of STEMI Guidelines: Reperfusion Strategies According to Patient Transportation
and Provider Site Presentation
Bainey, K.R. et al. J Am Coll Cardiol. 2016; 67(2):216–29.
Reperfusion strategies according to patient transportation (ambulance vs. self-presenter) and hospital-site presentation (PCI-capable hospital vs. non-PCI-capable
hospital), as stated by the 2012 ESC (European ﬂag) or the 2013 ACCF/AHA (American ﬂag) guideline recommendations. ACCF ¼ American College of Cardiology
Foundation; AHA ¼ American Heart Association; ESC ¼ European Society of Cardiology; FMC ¼ ﬁrst medical contact; PCI ¼ percutaneous coronary intervention;
STEMI ¼ ST-segment elevation myocardial infarction.
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221The ACCF/AHA guidelines recommend PCI of the
noninfarct artery at a time separate from primary PCI
in patients who have spontaneous symptoms of
myocardial ischemia (Class I, LOE: C). In patients with
intermediate- or high-risk ﬁndings on noninvasive
testing, PCI is also considered reasonable in a non-
infarct artery at a time separate from the primary PCI
(Class IIa, LOE: B). The ESC supports initial stress
testing or imaging (e.g., using stress myocardial
perfusion scintigraphy, stress echocardiography,
positron emission tomography, or cardiac magneticresonance imaging) for ischemia and viability in pa-
tients with multivessel disease or in whom revascu-
larization of other vessels is contemplated (Class I,
LOE: A).
Since the publication of the 2012 ESC STEMI
guidelines, a more recent ESC recommendation on
nonculprit intervention recommends that it be
considered as a staged approach in cases of symp-
tomatic ischemia (Class IIA, LOE: B), or even during
the index PCI in selected patients (Class IIB, LOE: B)
(5). In a 2015 focused update of the 2013 ACCF/AHA
TABLE 3 Acute Ancillary Pharmacotherapy According to Mode of Reperfusion
ACCF/AHA ESC Agreement
Primary PCI
Aspirin Class I, LOE: B Class I, LOE: B *
P2Y12 receptor inhibitor Class I, LOE: B Class I, LOE: A †
GP IIb/IIa inhibitor Class IIa, LOE: B Class IIb, LOE: B †
Upstream GP IIb/IIIa inhibitor Class IIb, LOE: B Class IIb, LOE: B *
UFH Class I, LOE: C Class I, LOE: C *
Bivalirudin (over UFH  GP IIb/IIIa) Class IIa, LOE: B Class I, LOE: B †
Enoxaparin (over UFH) NA Class IIb, LOE: B †
Fondaparinux Class III, LOE: B Class III, LOE: B *
Fibrinolysis
Aspirin Class I, LOE: A Class I, LOE: B †
Clopidogrel Class I, LOE: A Class I, LOE: A *
Anticoagulation up to 8 days or
revascularization
Class I, LOE: A Class I, LOE: A *
UFH Class I, LOE: C Class I, LOE: C *
Enoxaparin Class I, LOE: A Class I, LOE: A *
Fondaparinux Class I, LOE: B Class IIa, LOE: B †
*Agreement. †Disagreement.
GP ¼ glycoprotein; UFH ¼ unfractionated heparin; other abbreviations as in Table 1.
Bainey and Armstrong J A C C V O L . 6 7 , N O . 2 , 2 0 1 6
Transatlantic Comparison of STEMI Guidelines J A N U A R Y 1 9 , 2 0 1 6 : 2 1 6 – 2 9
222STEMI guidelines, the ACC/AHA and Society for Car-
diac Angiography and Interventions (SCAI) provide a
new recommendation on nonculprit PCI in selected
patients who are hemodynamically stable, either
during the index procedure or as a staged approach
(Class IIB, LOE: B) (6).
FIBRINOLYSIS. Although primary PCI is recom-
mended as the preferred mode of reperfusion in
STEMI, the feasibility of achieving this in a timely
fashion is much more challenging given geographic
constraints, transfer logistics, and recognition of the
total elapsed ischemic time. Hence, ﬁbrinolysis has
emerged as a reasonable and viable alternative.
Anc i l la ry pharmacolog ica l therapy . Table 3 pro-
vides a summary of acute pharmacotherapy for ﬁbri-
nolysis in STEMI. Both the ACCF/AHA and ESC
guidelines endorse DAPT with clopidogrel as standard
of care (age #75 years, 300-mg bolus followed by
75 mg daily) (Class I, LOE: A). However, the ACCF/AHA
guidelines recommend 75 mg only in patients age
>75 years (Class I, LOE: A), whereas the ESC guide-
lines make no ofﬁcial recommendation in the
elderly. Elderly patients were not excluded in
COMMIT (ClOpidogrel and Metoprolol in Myocardial
Infarction Trial) (26), where all patients received
a 75-mg clopidogrel load, followed by 75 mg
daily, as opposed to CLARITY-TIMI (Clopidogrel as
Adjunctive Reperfusion Therapy–Thrombolysis In
Myocardial Infarction)-28, where patients received a
300-mg bolus, followed by 75 mg daily (patients age
>75 years excluded) (27).On the basis of the ASSENT (Assessment of the
Safety and Efﬁcacy of a New Thrombolytic)-3 (28) and
EXTRACT-TIMI (Enoxaparin and Thrombolysis Re-
perfusion for Acute Myocardial Infarction Treatment–
Thrombolysis In Myocardial Infarction)-25 (29)
randomized studies, both guidelines strongly support
enoxaparin (compared with UFH) as the preferred
parenteral anticoagulant with ﬁbrinolysis (Class I,
LOE: A). Fondaparinux is recommended as Class I,
LOE: B by the ACCF/AHA guidelines, whereas the ESC
tempers its use as a Class IIa, LOE: B indication and,
further, recommends that it only be used in conjunc-
tion with streptokinase, given the results of the OASIS
(Organization for the Assessment of Strategies for
Ischemic Syndromes)-6 trial (30,31).
Early initiation. The ESC strongly supports initiation
of early ﬁbrinolysis (pre-hospital Class IIa, LOE: A)
in early-presenting patients (<2 h of symptoms) with
a large infarct territory and low bleeding risk when
FMC-to-device time exceeds 90 min (Class IIa,
LOE: B) (Table 2). This is largely on the basis of
NRMI (National Registry of Myocardial Infarction)
data, highlighting the potential beneﬁts of an early
presenting, young, anterior MI patient (i.e., a large
territory of myocardium at risk) (32). As noted previ-
ously, the ACCF/AHA guidelines are largely silent on
early (i.e., pre-hospital) administration.
When PCI is unavailable in patients with 12 to 24 h
of symptoms who have a large area of myocardium at
risk or hemodynamic instability, the ACCF/AHA
guidelines indicate that it is reasonable to administer
ﬁbrinolysis (Class IIa, LOE: C). The ESC guidelines do
not commit to a ﬁbrinolysis strategy beyond 12 h of
symptom duration.
Both guidelines support a rescue approach (Class I,
LOE: A), given the REACT (Rescue Angioplasty versus
Conservative Treatment or Repeat Thrombolysis) trial
supporting the need for rescue PCI when ﬁbrinolysis
fails (33,34). Because assessment of reperfusion is
paramount following ﬁbrinolysis, the ACCF/AHA
guidelines deﬁne ﬁbrinolysis failure electrocardio-
graphically as <50% ST-segment resolution in the
worst lead at 60 to 90 min following administration.
The ESC uses a shorter timeline of <50% ST-segment
resolution at 60 min.
Rout ine t ransfer to a PCI-capable hosp i ta l af ter
ﬁbr inolys i s . Following ﬁbrinolysis, a routine strat-
egy of transfer to a PCI-capable hospital may be
reasonable (Central Illustration), although logistical
constraints and ﬁnancial barriers may preclude such
a strategy for all STEMI patients. The ACCF/AHA
guidelines are more selective in their recommenda-
tion for transfer. Immediate transfer is suggested
for cardiogenic shock or severe acute heart failure,
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223irrespective of time delay from MI onset (Class I,
LOE: B). The approach taken for rescue intervention
for urgent transfer in cases of failed reperfusion or
reocclusion is classiﬁed as Class IIa, LOE: B or as part
of an invasive strategy in stable patients with PCI
between 3 and 24 h after successful ﬁbrinolysis
(Class IIa, LOE: B). The ACCF/AHA guidelines contend
that this is an unresolved issue, particularly in non–
high-risk patients after successful ﬁbrinolysis, and
requires further justiﬁcation. TRANSFER AMI (Trial of
Routine ANgioplasty and Stenting after Fibrinolysis
to Enhance Reperfusion in Acute Myocardial Infarc-
tion), which studied high-risk STEMI patients, found
that routine transfer to a PCI facility within 6 h
improved the 30-day composite outcome of death,
shock, heart failure, re-MI, and recurrent ischemia
(35). In contrast, the ESC guidelines take a more
aggressive uniﬁed approach, where transfer is indi-
cated in all patients (irrespective of baseline risk)
after ﬁbrinolysis (Class I, LOE: A).TABLE 4 Absolute and Relative Contraindications for Fibrinolysis
ACCF/AHA
Absolute Contr
Any prior intracranial hemorrhage
Known structural cerebral vascular lesion (e.g., arteriovenous
malformation)
Known malignant intracranial neoplasm (primary or metastatic)
Intracranial or intraspinal surgery within 2 months
Ischemic stroke within 3 months except acute ischemic
stroke within 4.5 h
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Signiﬁcant closed-head or facial trauma within 3 months
Severe uncontrolled hypertension (unresponsive to emergency
therapy)
For streptokinase, prior treatment within the previous 6 months
Relative Contr
Signiﬁcant hypertension on presentation (SBP >180 mm Hg or
DBP >110 mm Hg)
Traumatic or prolonged (>10 min) CPR
Pregnancy
Active peptic ulcer
Oral anticoagulant therapy
History of chronic, severe, poorly controlled hypertension
History of prior ischemic stroke >3 months
Dementia
Known intracranial pathology not covered in absolute contraindications
Major surgery (<3 weeks)
Recent (within 2 to 4 weeks) internal bleeding
Noncompressible vascular punctures
CPR ¼ cardiopulmonary resuscitation; DBP ¼ diastolic blood pressure; SBP ¼ systolic blContra ind icat ions to ﬁbr inolys i s . Both guidelines
report absolute and relative contraindications for
ﬁbrinolysis; however, inconsistencies between re-
ported contraindications are apparent (Table 4).
The ACCF/AHA guidelines are more liberal with
ﬁbrinolysis in patients with a prior ischemic stroke
compared with the ESC guidelines (3- vs. 6-month
history of prior ischemic stroke). However, the
ACCF/AHA guidelines are more conservative in pa-
tients with severe uncontrolled hypertension (abso-
lute contraindication), whereas the ESC guidelines
list this only as a relative contraindication. The ESC
does not recommend ﬁbrinolysis (absolute contrain-
dication) in patients with gastrointestinal bleeding
within the past month, or noncompressible punctures
within 24 h. These were considered relative con-
traindications by the ACCF/AHA. The ACCF/AHA
guidelines list prior use of streptokinase (within the
past 6 months) as an absolute contraindication, but
this is not mentioned in the ESC guidelines.ESC
aindications
Previous intracranial hemorrhage or stroke of unknown origin
at any time
Central nervous system damage or neoplasms or atrioventricular
malformation
Ischemic stroke in the preceding 6 months
Aortic dissection
Known bleeding disorder (excluding menses)
Recent major trauma/surgery/head injury (within the preceding
3 weeks)
Noncompressible punctures in the past 24 h (e.g., liver biopsy, lumbar
puncture)
Gastrointestinal bleeding within the past month
aindications
Refractory hypertension (SBP >180 mm Hg and/or DBP >110 mm Hg)
Prolonged or traumatic resuscitation
Pregnancy or within 1 week post-partum
Active peptic ulcer
Oral anticoagulant therapy
Transient ischemic attack in the preceding 6 months
Advanced liver disease
Infective endocarditis
ood pressure; other abbreviations as in Table 1.
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224MANAGEMENT OF COMPLICATIONS
FOLLOWING STEMI
In the reperfusion era, complications following STEM
have become less frequent (36).
SEVERE HEART FAILURE/CARDIOGENIC SHOCK. Both
the ACCF/AHA and ESC guidelines support emergent
revascularization (PCI or coronary artery bypass graft),
irrespective of MI onset, in the setting of shock (Class I,
LOE: B). However, when mechanical revascularization
is not available, the ACCF/AHA guidelines support
ﬁbrinolysis with a strong recommendation (Class I,
LOE: B), whereas the ESC’s stance is less enthusiastic
(Class IIa, LOE: C). The ACCF/AHA guidelines recom-
mend intra-aortic balloon pump use as reasonable in
shock (Class IIa, LOE: B), whereas the ESC guidelines
only indicate that its use should be considered
(Class IIb, LOE: B). The ESC provides extensive rec-
ommendations regarding the acute treatment of heart
failure and left ventricular dysfunction according to
Killip class. Examples include interval loop diuretic
use (i.e., furosemide 20 to 40 mg intravenous every
1 to 4 h) for Killip class II or III heart failure [Class I,
LOE: C]), inotropic support (dopamine, dobutamine),
including levosimendan for Killip class III heart failure
(Class IIb, LOE: C), and norepinephrine (preferred over
dopamine) when in cardiogenic shock (Killip class IV)
(Class IIb, LOE: B). Ultraﬁltration is considered for
Killip class III heart failure (Class IIa, LOE: B).
The ACCF/AHA guidelines provide limited guidanceTABLE 5 Management of Arrhythmias in the Acute Phase of STEMI
ACCF/AHA Recommendation
Atrial ﬁbrillation Refer to 2010 Advanced Cardiac Life
Support Guideline
Sustained VT/VF Refer to 2010 Advanced Cardiac Life
Support Guideline
Polymorphic VT Refer to 2010 Advanced Cardiac Life
Support Guideline
Symptomatic bradyarrhythmia
(sinus bradycardia, high-
grade AV block)
Temporary pacing if unresponsive to
medical management (i.e., atropine;
Class I, LOE: C)
AV ¼ atrioventricular; CCB ¼ calcium-channel blocker; HF ¼ heart failure; STEMI ¼ ST-s
tachycardia; other abbreviations as in Table 1.regarding pharmacological management in this area,
but state, “Medical support with inotropes and vaso-
pressor agents should be individualized and guided by
invasive hemodynamic monitoring. The use of dopa-
mine in this setting may be associated with excess
hazard” (4).
ARRHYTHMIAS. The ESC guidelines provide numerous
practice recommendations for acute management of
these conditions, whereas the ACCF/AHA guidelines
largely refer to the 2010 Advanced Cardiac Life Support
guidelines for care as a web-based teaching tool (with
no mention of Class or LOE distinction on the website)
(Table 5).
MANAGEMENT OF HYPERGLYCEMIA IN THE
ACUTE PHASE OF STEMI
The beneﬁt afforded by intravenous insulin in control
of hyperglycemia was noted in the DIGAMI (Diabetes
Mellitus Insulin-Glucose Infusion in Acute Myocardial
Infarction) trial (37), but could not be replicated
in the DIGAMI-2 study (38). Moreover, no beneﬁt
toward intensive glucose control was evident in the HI
(Hyperglycemia: Intensive Insulin Infusion in
Infarction)-5 trial in acute MI (39). Given this ambigu-
ity, the ACCF/AHA guidelines stated that blood
glucose should be maintained at <180 mg/dl, while
avoiding hypoglycemia. Yet, the ESC devotes an entire
section of the guidelines to management of hypergly-
cemia in the acute phase of STEMI. The goals of glucose
control in the acute phase are maintenance of glucoseESC Recommendation
 Rate control with IV beta-blocker or non-dihydropyridine CCB if
no HF (Class I, LOE: A)
 Amiodarone or IV digitalis for rapid rate with HF or hypotension
(Class I, LOE: B)
 Electrical cardioversion when unstable (Class I, LOE: C)
 Chemical cardioversion (IV amiodarone in stable patients with
recent onset and structural heart disease (Class I, LOE: A)
 Direct current cardioversion (Class I, LOE: C)
 Transvenous pacing could be considered if refractory to cardio-
version or frequent recurrence (Class IIa, LOE: C)
 Sustained monomorphic VT refractory to cardioversion or recur-
rent could be treated with IV amiodarone (Class IIa, LOE: C), IV
lidocaine (Class IIb, LOE: C), or IV sotalol (Class IIb, LOE: C)
 Treat with IV beta-blocker (Class I, LOE: B) or IV amiodarone
(Class I, LOE: C) or IV lidocaine (Class IIb, LOE: C)
 Can be treated with overdrive pacing with a transvenous pacer or
isoproterenol (Class IIa, LOE: C)
 Correct reversible causes (electrolytes (Class I, LOE: C), urgent
angiography for ischemia (Class I, LOE: C)
 Temporary pacing if unresponsive to medical management
(i.e., atropine; Class I, LOE: C)
egment elevation myocardial infarction; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular
TABLE 6 Secondary Prevention Following STEMI
ACCF/AHA ESC Agreement
Aspirin Class I, LOE: A
(81–325 mg)
Class IIa, LOE: B
(81 mg)
Class I, LOE: A
(75–100mg)
*
P2Y12 receptor antagonist (12 months) Class I, LOE: B Class I, LOE: C *
Beta-blockers Class I, LOE: B Class IIa, LOE: B *
ACE inhibitor with LV systolic
dysfunction, heart failure, or
anterior location
Class I, LOE: A Class I, LOE: A †
ACE inhibitor routinely Class IIa, LOE: A Class IIa, LOE: A †
ARB as a substitute for ACE inhibitor
due to intolerance
Class I, LOE: B Class I, LOE: B †
Aldosterone antagonist with LVEF
<40% and heart failure or diabetes
Class I, LOE: B Class I, LOE: B †
High-dose statins Class I, LOE: B Class I, LOE: A *
Cardiac rehabilitation Class I, LOE: B Class I, LOE: B †
Smoking cessation Class I, LOE: A Class I, LOE: B *
*Disagreement. †Agreement.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; LV ¼ left ventricular; LVEF ¼ left
ventricular ejection fraction; other abbreviations as in Tables 1 and 5.
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225concentrations #11.0 mmol/l (200 mg/dl), while
avoiding a fall of glycemia <5 mmol/l (<90 mg/dl). In
some patients, this may require a dose-adjusted insu-
lin infusion with monitoring of glucose, as long as
hypoglycemia is avoided (Class IIa, LOE: B).
LOGISTICS OF INTENSIVE CARE
The ACCF/AHA guidelines do not provide recom-
mendations pertaining to the logistics of intensive
care. However, as part of risk assessment for STEMI,
the guidelines support early discharge of stable
STEMI patients with a low risk of complications. In
particular, among patients with STEMI managed with
ﬁbrinolysis, it has been suggested that an uncompli-
cated course after 72 h of hospitalization identiﬁes a
group with sufﬁciently low risk to enable discharge
and is cost-effective (40,41). In comparison, the ESC
provides 4 detailed recommendations pertaining to
logistical issues for hospital stay with STEMI. In
particular, the ESC guidelines reference the results of
the PAMI II (Second Primary Angioplasty in Myocar-
dial Infarction Trial) criteria (42) and the Zwolle pri-
mary PCI Index (43), promoting early discharge (after
approximately 72 h) in selected low-risk patients,
provided early rehabilitation and adequate follow-up
can be arranged (Class IIb, LOE: B).
SECONDARY PREVENTION
Patients presenting with STEMI are at risk of recur-
rent events and early death (44). With the use of
evidence-based treatments, clinical outcomes have
improved over time (45). Table 6 provides a brief
summary of long-term therapies advocated by each
guideline task force for comparison. Although most
recommendations are similar, important distinctions
are worthy of discussion. The ACCF/AHA guidelines
make a less deﬁnitive recommendation on the use of
maintenance low-dose aspirin (Class IIa, LOE: B)
compared with the ESC guidelines (Class I, LOE: A).
The European guideline position on low-dose aspirin
is supported by the CURRENT-OASIS (Clopidogrel
optimal loading dose Usage to Reduce Recurrent
EveNTs-Organization to Assess Strategies in Ischemic
Syndromes)-7 trial, which demonstrated no clear
efﬁcacy and a higher risk of gastrointestinal bleeding
compared with regular-dose aspirin (46). Both
guidelines support 12 months of P2Y12 inhibitors;
however, only the ESC guidelines recommend gastric
protection with a proton pump inhibitor in patients
on DAPT with a high risk of bleeding complications
(Class IIa, LOE: C). The ACCF/AHA guidelines strongly
recommend long-term beta-blockers (Class I, LOE: B),
whereas the ESC provides a weaker recommendation(Class IIa, LOE: B). Both guidelines strongly recom-
mend angiotensin-converting enzyme inhibitors,
particularly in patients with left ventricular systolic
dysfunction, heart failure, or anterior location, but
the ESC guidelines also add diabetic status as an
indication (Class I, LOE: A). Both guidelines list high-
dose statin therapy as a Class I recommendation;
however, the ACCF/AHA guidelines grade it with a
lower level of evidence (LOE: B; ESC LOE: A). Finally,
the ESC recommends the use of low-dose rivaroxaban
(2.5 mg twice daily) in selected patients who receive
aspirin and clopidogrel, provided that the bleeding
risk proﬁle is acceptable (Class IIb, LOE: B). This is
primarily supported by the results of the ATLAS ACS
2-TIMI-51 (Anti-Xa Therapy to Lower Cardiovascular
Events in Addition to Standard Therapy in Subjects
With Acute Coronary Syndrome ACS 2–Thrombolysis
In Myocardial Infarction-51) trial (47), which has led
to European Medicines Agency approval, but rivar-
oxaban has yet to be approved by the U.S. Food and
Drug Administration.
SUDDEN CARDIAC DEATH RISK ASSESSMENT
The most powerful predictor of sudden cardiac death
is reduced left ventricular function (48). In acute MI,
left ventricular systolic dysfunction is common, but
incremental recovery of stunned myocardium often
occurs over a 3-month interval after reperfusion.
Hence, re-evaluation of left ventricular function is of
fundamental importance in the nonacute setting.
The ACCF/AHA guidelines indicate that patients
with an initially reduced left ventricular ejection
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226fraction (LVEF) (i.e. #40%) who are possible im-
plantable cardioverter-deﬁbrillator (ICD) candidates
should undergo re-evaluation of LVEF $40 days
after discharge (Class I, LOE: B). If the LVEF
remains #35% with symptoms (or #30% without
symptoms), an ICD is recommended (49). The ESC
makes a similar recommendation with an even
stronger level of evidence (Class I, LOE: A). However,
in the text, the ESC suggests postponing re-evaluation
of left ventricular function until 3 months after
revascularization procedures to allow adequate time
for recovery of LV function.
CONSIDERATIONS FOR FUTURE GUIDELINES
With the evolving progress in STEMI care, subsequent
iterations of guideline recommendations require
incorporation of the most contemporary evidence-
based studies. For instance, the optimal reperfusion
strategy for early presenters with STEMI has been
recently informed by the STREAM (Strategic Reperfu-
sion Early After Myocardial Infarction) trial supporting
early ﬁbrinolysis as a legitimate alternative to primary
PCI in patients who cannot undergo timely interven-
tion (50). Moreover, an additional pre-speciﬁed
STREAM analysis, stratiﬁed by delays in primary PCI,
indicates similarity between an early ﬁbrinolysis
approach and primary PCI at 50 to 60 min, but superi-
ority over primary PCI emerged if the PCI-related delay
extended beyond 90 min (51). Hence, the optimal time
for “PCI-related delay” deserves re-evaluation.
Regarding optimal anticoagulant pharmacotherapy
in primary PCI, the EUROMAX (European Ambulance
Acute Coronary Syndrome Angiography) trial
randomizing primary PCI patients to pre-hospital
bivalirudin or heparin (roughly 40% did not receive
a GP IIb/IIIa antagonist) found no difference in 30-day
death with bivalirudin (although bleeding was
reduced). However, safety concerns were conveyed,
given the higher risk of acute stent thrombosis seen in
patients treated with bivalirudin (52). More recently,
the HEAT-PPCI (How Effective are Antithrombotic
Therapies in Primary Percutaneous Coronary Inter-
vention) trial of primary PCI patients randomized to
heparin versus bivalirudin (balanced use of GP IIb/IIIa
antagonists) found a higher risk of major adverse
events with bivalirudin, with no reduction in
bleeding. Furthermore, a higher incidence of stent
thrombosis was noted (53). Hence, in contemporary
practice with more potent P2Y12 receptor agents
(hence lower GP IIb/IIIa inhibitor use), bivalirudin use
will warrant re-evaluation in the future.
Recommendations for radial access site in STEMI
may also garner strengthened support in futureguidelines. Since publication of the guidelines, a
multitude of randomized studies have attempted to
address the beneﬁts of radial versus femoral access in
ACS. The latest MATRIX (Minimizing Adverse Hem-
orrhagic Events by Transradial Access Site and Sys-
temic Implementation of Angiox) trial of ACS patients
found improvements in clinical outcomes with radial
access and a lower rate of major bleeding at 30 days.
Furthermore, all-cause mortality was reduced with
the radial access approach (54). The MATRIX authors
also performed a meta-analysis of MATRIX (54),
RIVAL (21), RIFLE-STEACS (Radial Versus Femoral
Randomized Investigation in ST-Elevation Acute
Coronary Syndrome) (55), and STEMI-RADIAL (ST
Elevation Myocardial Infarction treated by RADIAL or
femoral approach) (56), showing a reduction in death
and non–coronary artery bypass graft major bleeding
with radial cardiac catheterization (54).
Most recently, the recommendations on perform-
ing nonculprit intervention have been challenged by
new randomized studies of modest size supporting
routine complete revascularization with PCI in
STEMI patients with multivessel disease during the
index cardiac catheterization (PRAMI [Preventive
Angioplasty in Acute Myocardial Infarction] [57],
CVLPRIT [Complete Versus culprit-Lesion only
PRimary PCI Trial] [58]) or as a staged PCI (DANAMI
[DANish Study of Optimal Acute Treatment of Pa-
tients With ST-elevation Myocardial Infarction]-3 and
PRIMULTI [Primary PCI in Patients With ST-elevation
Myocardial Infarction and Multivessel Disease:
Treatment of Culprit Lesion Only or Complete
Revascularization] [59]). The large, well-powered,
ongoing, international, multicenter COMPLETE
(Complete versus Culprit-only Revascularization to
Treat Multi-vessel Disease after Primary PCI for
STEMI) trial is expected to deﬁnitively address the
optimal revascularization strategy in STEMI patients
with multivessel disease undergoing primary PCI
(60). Finally, both sets of guideline recommenda-
tions list aspiration thrombectomy in STEMI as Class
IIa, LOE: B. However, the results of the TASTE
(Thrombus Aspiration in ST-Elevation myocardial
infarction in Scandinavia) (61) and TOTAL (Trial of
Routine Aspiration Thrombectomy with PCI versus
PCI Alone in Patients with STEMI) (62) studies have
challenged the utility of routine aspiration in STEMI,
showing no beneﬁts in clinical outcomes (including
survival), with the possibility of harm (increased risk
of stroke seen in TOTAL [63]). This recommendation
has now been downgraded by the ACC/AHA/SCAI
2015 focused update to Class III, LOE: A for routine
aspiration and to Class IIb, LOE: C as a bailout
procedure (6).
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227CONCLUSIONS
It appears that legitimate reasons exist for both the
ACCF/AHA and the ESC to maintain separate guide-
lines for STEMI, given their different target audi-
ences, available medicines, and resources (64).
However, alignment on levels of evidence from the
same sources seems desirable, and may even be
facilitated by the recent move of the ACCF/AHA to-
ward engaging a separate evidence review committee
comprised of methodologists, epidemiologists, and
biostatisticians (65). This process would be clearly
enhanced by an appropriately constituted single
group derived from both sides of the Atlantic that
facilitate optimizing STEMI networks and care (66).
The continuing escalation in health care costs will
preclude or substantially inhibit the introduction ofcertain novel therapies in some countries and re-
gions. Hence, the introduction of an economic-based,
return-on-investment framework that helps to
address the potential cost-effectiveness of the rec-
ommendations would be welcome. Finally, harness-
ing the power of electronic media to bring these
elements together nimbly at the patient-provider
interface shows great promise in ensuring knowl-
edgeable application of guidelines by practitioners at
the clinical interface.
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